Literature DB >> 3145076

Anticoagulant drugs in the elderly: the risks usually outweight the benefits.

P J Scott1.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3145076      PMCID： PMC1834741          DOI： 10.1136/bmj.297.6658.1261

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  32 in total

1.  Age as a determinant of sensitivity to warfarin.

Authors:  A M Shepherd; D S Hewick; T A Moreland; I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

Review 2.  Diagnosis of deep-vein thrombosis.

Authors:  N Browse
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

3.  Efficacy and toxicity of heparin in relation to age and sex.

Authors:  H Jick; D Slone; I T Borda; S Shapiro
Journal:  N Engl J Med       Date:  1968-08-08       Impact factor: 91.245

Review 4.  Bleeding associated with antithrombotic therapy.

Authors:  J G Kelton; J Hirsh
Journal:  Semin Hematol       Date:  1980-10       Impact factor: 3.851

5.  Prediction and selective prophylaxis of venous thrombosis in elective gastrointestinal surgery.

Authors:  G D Lowe; D H Osborne; B M McArdle; A Smith; D C Carter; C D Forbes; D McLaren; C R Prentice
Journal:  Lancet       Date:  1982-02-20       Impact factor: 79.321

6.  Problems encountered in long-term treatment with anticoagulants.

Authors:  S Husted; F Andreasen
Journal:  Acta Med Scand       Date:  1976

7.  Is pulmonary angiography essential for the diagnosis of acute pulmonary embolism?

Authors:  J O Menzoian; L F Williams
Journal:  Am J Surg       Date:  1979-04       Impact factor: 2.565

8.  Heparin therapy in venous thromboembolism.

Authors:  J E Wilson; L J Bynum; R W Parkey
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

9.  Pulmonary embolism in the elderly.

Authors:  W Busby; A Bayer; J Pathy
Journal:  Age Ageing       Date:  1988-05       Impact factor: 10.668

10.  Value of anticoagulants in the treatment of pulmonary embolism: a discussion paper.

Authors:  P Egermayer
Journal:  J R Soc Med       Date:  1981-09       Impact factor: 18.000
View more
  7 in total

1.  Safety of anticoagulation in the elderly: reasons for discontinuing therapy.

Authors:  P A O'Neill; D Crossley; D A Taberner; D S Fairweather
Journal:  Postgrad Med J       Date:  1992-10       Impact factor: 2.401

2.  Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage.

Authors:  R Fogelholm; K Eskola; T Kiminkinen; I Kunnamo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

Review 3.  Adverse reactions as a cause of hospital admission in the aged.

Authors:  K Beard
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

4.  Risk-benefit analysis: from a logical point of view.

Authors:  Georg Spielthenner
Journal:  J Bioeth Inq       Date:  2012-03-21       Impact factor: 1.352

Review 5.  Adverse drug reactions. An overview of special considerations in the management of the elderly patient.

Authors:  L A Brawn; C M Castleden
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

6.  Factors affecting the precision of warfarin treatment.

Authors:  R P Britt; A H James; C L Raskino; S G Thompson
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

7.  Effect of age upon the induction and maintenance of anticoagulation with warfarin.

Authors:  J R Gladman; G Dolan
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.